ASTRAZENECA PLC
Company website sourced- Local ticker
- AZN
- ISIN
- GB0009895292
- Exchange
- London Stock Exchange, XLON
- Primary market
- United Kingdom
Figures as of 6 November 2026, 18:00 UTC. Refreshed weekly.
What we hold
Counted over 22 years, by bundle.
Counts are classified documents, not pages. A name with no filings in a bundle still shows the bundle, so an empty row is a fact about the company rather than a gap in coverage.
| Bundle | Documents held | Most recent |
|---|---|---|
| Core Financials & GovernanceAnnual and interim reports, financial statements, AGM and remuneration material | 326 | 30 Oct 2026AstraZeneca results: 9M and Q3 2026 |
| Corporate EventsAnnouncements, results releases, corporate actions, director dealings | 2,381 | 2 Nov 2026Notification of Admission of Further Securities to Trading (PRM 1.6.4R) |
| Earnings IntelligenceEarnings call transcripts, results presentations, capital markets days | 177 | 30 Oct 2026Q3 2026 Results Update – Clinical Trials Appendix |
| Sustainability & PoliciesSustainability reports, transition plans, supplier and human rights policies | 97 | 1 Jul 2026Horseshoe Crabs: Nature Action Case Study |
| MiscellaneousEverything the taxonomy places outside the four bundles above | 1,108 | 2 Nov 2026Total Voting Rights |
| All bundles | 4,030 |
Most recent documents
The ten most recent, newest first. Every document carries the date it was published, the classification we assigned, and its length.
The full record for ASTRAZENECA PLC, every document in it and the whole archive behind it, is in Orbit Insight. Opening a document costs one credit and trial accounts start with 500.
| Document | Bundle | Published | Pages | Open |
|---|---|---|---|---|
| Notification of Admission of Further Securities to Trading (PRM 1.6.4R)Regulatory Disclosure | Events | 2 Nov 2026 | 2 | Open in Insight |
| Total Voting RightsMiscellaneous | Other | 2 Nov 2026 | 1 | Not yet openable |
| Foreign Issuer Report, Report of foreign issuer [Rules 13a-16 and 15d-16]Current Report Filings | Events | 2 Nov 2026 | 2 | Open in Insight |
| Notification notification of Admission of Further Securities to Trading (PRM 1.6.4R)Miscellaneous | Other | 2 Nov 2026 | 4 | Not yet openable |
| AstraZeneca results: 9M and Q3 2026Quarterly Reports | Financials | 30 Oct 2026 | 34 | Open in Insight |
| Q3 2026 Results Update – Clinical Trials AppendixConference Call Presentation | Earnings | 30 Oct 2026 | 153 | Open in Insight |
| 9M and Q3 2026 Results Conference Call PresentationConference Call Presentation | Earnings | 30 Oct 2026 | 46 | Open in Insight |
| AstraZeneca results: 9M and Q3 2026Interim reports | Financials | 30 Oct 2026 | 41 | Open in Insight |
| AstraZeneca results: 9M and Q3 2026Miscellaneous | Other | 30 Oct 2026 | 2 | Not yet openable |
| Q3 2026Earnings Call Transcript - ECM | Earnings | 30 Oct 2026 | 24 | Open in Insight |
How it reaches you. And how fast.
The same facts are attached to every name in the universe, which is what makes a coverage answer checkable rather than a claim.
Open the full United Kingdom coverage detail for the exchanges behind that company count, what the year’s volume is made of, and how the median latency is distributed.
Follow ASTRAZENECA PLC and the rest of your universe.
Paste every name you hold into Orbit Insight and get this view for all of them, plus the documents themselves. Trial accounts start with 500 credits.
Missing a filing for GB0009895292?
If a document you expect for this name is not held, tell us which one and we will assess a backfill.